Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Slides:

Advertisements

Similar presentations

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Advertisements

Figure 1 The heterogenous landscape of triple-negative breast cancer

Figure 1 Estimated annual percentages of new

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Response after initial increase in total tumour burden

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Concept of the therapeutic index

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Generations of cancer vaccine antigens

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 6 Double opposed-field irradiation of an idealized geometry

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 3 Algorithm for the determination of the clinical

Figure 4 Angiogenic signalling network and inhibition by antiangiogenic drugs Figure 4 | Angiogenic signalling network and inhibition by antiangiogenic.

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Critical signalling pathways involved in PDAC pathogenesis

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Approaches to improve CAR-T-cell therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Figure 2 Frequency and overlap of alterations

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Somatic and germ-line TP53 mutations in cancer

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Figure 2 Effect of chromosomal instability tolerance

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 4D printing schemes and time-evolving structure geometries

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Gene-expression quantification methods

High-throughput drug screen (HTDS) reveals ARS1620 and PI3K pathway inhibitors synergies and a heterogeneous pattern of RTK synergies. High-throughput.

Presentation transcript:

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer Figure 5 | Mutational heterogeneity in oesophageal and gastric cancer. Mutation frequencies observed in exomes from 3,083 tumour–normal pairs are shown [L153]. Each dot corresponds to a tumour–normal pair, with vertical position indicating the total frequency of somatic mutations in the exome. Tumour types are ordered by their median somatic mutation frequency, with the lowest frequencies (left) found in haematological and paediatric tumours, and the highest frequencies (right). The lowest and highest mutation frequencies vary more than 1,000-fold across different cancers and also within several tumour types. The bottom panel shows the relative proportions of the six different possible base-pair substitutions, as indicated in the legend on the left. Reproduced with permission © Lawrence, M. S. et al. Nature 499, 214–218 (2013)152. Reproduced with permission © Lawrence, M. S. et al. Nature 499, 214–218 (2013) Lordick, F. & Janjigian, Y. Y. (2016) Clinical impact of tumour biology in the management of gastroesophageal cancer Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.15